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Abstract 
Digestion of the proteinase inhibitor aprotinin, by clostripain, a cysteine proteinase, yielded five oligopeptide fragments. Two fragments exhibited 
both antiviral and antibacterial ctivities, two fragments only antiviral activity, and one fragment showed no antimicrobial ctivity. One of the former 
oligopeptides showed antiviral activity against human herpes implex virus type 1 and bovine parainfluenza virus type 3. It consisted of the hexapeptide 
Y-F-Y-N-A-K corresponding to amino acids 21-26 of intact aprotinin. An identical synthetic pcptide had the same antiviral spectrum as the natural 
hexapeptide, exhibited no antibacterial ctivity, and was also devoid of trypsin inhibiting activity. Intact aprotinin, in contrast, is ineffective against 
human herpes implex virus 1 and bovine parainfluenza virus 3 but possesses antibacterial properties against several bacterial species [(1992) J. Appl. 
Bact. 72, 180-187]. 
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1. Introduction 2. Materials and methods 
Aprotinin, also known as bovine pancreatic trypsin 
inhibitor, is one of the most studied proteinase inhib- 
itors. It has been isolated from bovine organs and tissues 
[1-3], and aprotinin-like inhibitors have been found in 
several organisms [4,5]. Although isolated in 1930 [6] and 
extensively studied since then, its precise biological func- 
tion remains unknown [7]. 
One property of aprotinin is its antimicrobial ctivity. 
It inhibits the growth of several Gram-positive and 
-negative bacteria [8] and the replication of influenza 
viruses [9,10]. Both antibacterial nd antiviral activities 
have been attributed to the proteinase inhibitory func- 
tion of aprotinin. 
We recently reported that the bactericidal nd antipro- 
teolytic activities of aprotinin are not related and sug- 
gested that the bactericidal potency of aprotinin is due 
instead to its cationic and hydrophobic properties [11]. 
The purpose of this study was to determine if the 
antimicrobial ctions of aprotinin require the intact mo- 
lecular conformation or whether discrete peptide se- 
quences within the molecule can fulfil this function. 
Aprotinin was digested by the proteinase, clostripain, to 
yield 5 fragments, one of which had potent antiviral 
activity. We have completely characterized and syntheti- 
cally produced this fragment. Its properties are discussed 
in this report. 
*Corresponding author. Fax: (41) (1) 365 1323. 
2.1. Materials 
Reagents were obtained from the following sources: aprotinin (Con- 
trykal 50000) was a gift from Prof. Oettel, VEB Pharmazeutisches 
Kombinat GERMED, Dresden (Germany); clostripain, methyl cellu- 
lose crystal violet and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra- 
zolium Cbromide (MTT) were from Sigma; trypsin (from porcine pan- 
creas) was from Serva; Fmoc-amino acid derivatives and Fmoc-Lys 
(t-Boc)-Resin were from Bachem (Switzerland); ProRPC (Hr 5/10 and 
HR 16/10) and PepRPC Hr 5/5 columns for reverse-phase chromatog- 
raphy were from Pharmacia; Bio Gel P-2 fine was from Bio-Rad; 
Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923 
were from Roche; Klebsiella pneumoniae ATCC 13883, Serratia marces- 
cens ATCC 8100, Staphylococcus epidermitis ATCC 12228 were from 
Eurodiagnostic, Shoreham-By Sea, Brighton; Staphylococcus lentus 
and Bordetella bronchiseptica wild-type strains were from the Institute 
of Bacteriology of the Veterinary Hospital Zfirich; Bacillus subtilis 
BGA was from Merk; Eagle's minimum essential medium with L-glu- 
tamine was from Amimed; 24- and 96-well plates were from Nunc; 
Madin-Darby bovine kidney cells (MDBK) and pooled New Zealand 
white rabbit kidney cells (LLC-RK1) were from Flow laboratories; 
Rhabdomyosarkom cells (RD) and human herpes implex virus type 
1 (HSV-1) were a gift of Dr. Wunderli from the Institute for Immunol- 
ogy and Virology, University of Ziirich; African green monkey kidney 
cells (VERO), swine testis cells (ST), equine herpes virus type 1 (EHV- 
1), bovine parainfluenza virus type 3 (PI-3) and porcine respiratory 
corona virus (PRCV) were from the Institute of Veterinary Virology, 
Ziirich; embryonic horse lung cells (EHL) were prepared in our Insti- 
tute from normal aborted fetuses at 3 months of gestation. 
All chemicals for sequence analysis were purchased from Applied 
Biosystems Inc. Solvents and reagents used for peptide synthesis were 
purchased from Fluka. 
2.2. Antibacterial ssays 
Single colonies of bacteria grown on trypticase soy agar plates were 
inoculated in 50 ml of trypticase soy broth (TSB) and grown overnight 
at 37°C. 1 ml of bacterial suspension was diluted 1:50 with TSB. Bacte- 
ria were grown at 37°C and logarithmic phase organisms were har- 
vested at a density of 14  x 108 cfu per ml. The culture was then centri- 
fuged at 2,000 x g for 10 min. The sedimented bacteria were washed 
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twice with 10 mM sodium phosphate buffer, pH 7.4, and adjusted to 
106 cfu per ml. 50/11 of bacterial suspension was added to 50/zl of test 
solution. 100,ul of 2% TSB in 10 mM sodium phosphate buffer was then 
added. The mixture was incubated at 37°C for 2 h, serially ten-fold 
diluted from 1:10 to 1:1,000 in 10 mM sodium phosphate buffer, pH 
7.4, and plated on trypticase soy agar. The plates were incubated for 
2448 h at 37°C until distinct colonies could be counted. All assays were 
carried out in duplicate. 
2.3. Antiviral assays 
The antiviral activity of aprotinin and its fragments was performed 
as follows: samples were dissolved in Eagle's minimum essential me- 
dium (serum free) containing 30 mM HEPES and antibiotics (100 U/ml 
penicillin and 100/.tg/ml streptomycin). Cells were grown to 90% con- 
fluency in 96-well plates and then infected with 104 tissue culture infec- 
tive dose of 50% (TCIDs0) of virus. After incubation for 60 min at 37 ° C, 
the non-adsorbed virus was discarded. The infected cells were washed 
with phosphate buffered saline (PBS) and then incubated with 50 ]tl of 
the sample prepared as described above. The cell cultures were incu- 
bated until a clearly detectable cytopathic effect (CPE) in unprotected 
infected cells was visible (about 24 h). Uninfected cells were incubated 
with the test substances without virus to evaluate their cytotoxicity. 
Antiviral assays were performed for each virus in a homologue system: 
HSV-1 on the human RD cell line, EHV-1 on the equine cell line EHL, 
PI-3 on the bovine cell line MDBK, and PRCV on the porcine cell line 
ST. Additionally HSV-1 and EHV-1 were tested in a heterologous 
system (VERO cells). 
Quantification ofHSV-1 inhibition was performed by plaque reduc- 
tion assay as follows. Plates from the antiviral assay were frozen and 
thawed three times, supernatants were serially tenfold diluted in 
Eagle's minimal essential medium, and inoculated into the appriopriate 
cell monolayers grown in 24-well plates (VERO cells for HSV-1 and 
LLC-RK1 for EHV-I). Inoculations were performed with 250/zl super- 
natant for 60 min at 37°C. Cells were then washed and overlaid 
with Eagle's minimal essential medium containing 5% fetal calf 
serum and 0.8% (w/v) methyl cellulose and incubated at 37°C, 5% CO2 
in a humid atmosphere until plaques were visible (48-72 h). Methyl 
cellulose medium was then removed, the cultures were fixed with meth- 
anol and finally stained with 0.5% Crystal violet and the plaques 
counted. 
Quantification of PI-3 inhibition were performed by MTT assay 
modified from [12,13] as follows. Plates from the antiviral assay were 
frozen and thawed three times, supernatants were serially tenfold di- 
luted in Eagle's minimal essential medium, and inoculated to MDBK 
cell monolayers grown in 24-well plates. Inoculations were performed 
with 250/zl supernatant for 60 min at 37°C. Ceils were then washed and 
overlaid with 1 ml Eagle's minimal essential medium containing 2% 
fetal calf serum and incubated at 37°C, 5% CO2 in a humid atmosphere 
until clear damage of the monolayers was visible (3-4 days). Superna- 
tant was then carefully removed and substituted with 0.5 ml fresh 
Eagle's minimal essential medium without fetal calf serum containing 
1.25 mg/ml of MTT. After incubation for 1 h at 37°C, 0.5 ml of acidified 
isopropanol (2 ml of concentrated HC1 per 500 ml of isopropanol) 
containing 10% (v/v) Triton X-100 was added to each well. After solu- 
bilisation of the cells and of the blue cristals (30 min), the A57o, which 
is inversely proportional to the extent of cell destruction, was read. 
Inhibition was calculated as the percent reduction in cell damage of 
Y-F-Y-N-A-K treated infected cultures compared to untreated infected 
cultures. 
2.4. Assay for trypsin inhibitory capacity 
The assay for the antitryptic activity was performed with N-benzoyl- 
L-arginine-p-nitroanilide asthe substrate according to the method of 
Geiger and Fritz [14]. 
2.5. Peptide concentration 
Peptide concentration was determined photometrically according to 
Gill et al. [15]. An extinction coefficient of 2,560 M 1. cm 1 was as- 
sumed. 
2.6. Sequence analysis of antiviral peptide 
Sequence analysis was performed on a Model 470 A/970 A gas-phase 
sequencer (Applied Biosystem Inc.) equipped with an on-line PTH- 
amino acid analyzer Model 120 A (Applied Biosystem Inc.) using stand- 
ard chemicals and programs. 
2. 7. Preparation of the synthetic peptide 
Synthesis of Y-F-Y-N-A-K was performed on an Applied Biosys- 
tems Inc. Model 430 A Peptide Synthesizer. The hexapeptide was 
synthesized according to the FastMoc strategy using 2-(1-H-benzo- 
triazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate s the 
activating agent [16]. The peptide was deprotected and cleaved from the 
resin by incubation in a mixture of 0.75 g crystalline phenol, 0.25 ml 
ethanedithiol, 0.5 ml thioanisole, 0.5 ml water and 10 ml trifluoroacetic 
acid. 
The cleaved peptide was collected by precipitation i t-butylmethyl- 
ether and then centrifuged. The pellet was collected and washed several 
times with t-butylmethylether. Aliquots of the peptide were dissolved 
in 5% (v/v) acetic acid and purified (see below). 
2.8. Purification of commercial protinin by FPLC reverse-phase 
chromatography 
12 mg aprotinin was dissolved in 2 ml 0.3% trifluoroacetic a id and 
loaded onto a ProRPC (Hr 16/10) column equilibrated with 0.3% tri- 
fluoroacetic acid. The column was eluted at a flow rate of 3 ml/min and 
fractions of 2 ml were collected. After collecting 5 fractions, a linear 
gradient from 0 to 30% (v/v) acetonitrile (80 ml vol.) was applied. 
Aprotinin was eluted as a single peak. Fractions corresponding to the 
peak were pooled and then freeze-dried. 
2.9. Digestion of aprotinin with clostripain 
Clostripain was activated as follows: 100 U of clostripain were dis- 
solved in 500 ,ul of 50 mM Tris-HC1 buffer, pH 7.5, containing 10 mM 
CaC12, 160 mM NaCI, 2.5 mM DTT, and incubated for 3 h at room 
temperature. The enzyme solution was then stored at 4°C until used 
(not longer than 24 h). 
10 mg of purified aprotinin was dissolved in 1.5 ml of Tris buffer, pH 
7.5, and added to 500/4 of clostripain solution. The mixture was then 
incubated at 37°C for 24 h and then cleared by centrifugation at
20,000 x g for 15 rain. 
2.10 Separation of aprotinin fragments 
2. l & L FPLC reverse-phase chromatography onProRPC ( Hr 16/10). 
To the clostripain-digested aprotinin was added trifluoroacetic a id 
to a final concentration f 0.3% (v/v). The solution (2.5 ml total) was 
applied to the ProRPC column which was previously equilibrated with 
0.3% trifluoroacetic acid in 10% acetonitrile (v/v). The column was 
eluted at a flow rate of 2 ml/min and fractions of 2 ml were collected. 
After collecting 10 fractions a linear gradient from 10 to 60% acetoni- 
trile (v/v) was applied. Respective peak fractions were pooled and 
freeze-dried. The dried samples were dissolved in 700/.tl H20 and 
assayed for antiviral activity against HSV-1. 
2.10.2. FPLC reverse-phase chromatography onProRPC (Hr 5/10). 
Pool II derived from the separation of the aprotinin fragments was 
acidified with trifluoroacetic a id (final concentration 0.3% (v/v)) and 
loaded onto a ProRPC column which was equilibrated with 0.3% tri- 
fluoroacetic acid. The column was eluted at a flow rate of 0.5 ml/min 
and fractions of 0.5 ml were collected. After collecting four fractions, 
a linear gradient from 0 to 60% acetonitrile was applied. The peak 
fractions were pooled, freeze-dried and sequenced. 
2.11. Purification of the synthetic antiviral peptide fragment 
Aliquots of the synthetic peptide dissolved in 5% (v/v) acetic acid 
were first purified by gel-filtration through a Bio-Gel P-2 column 
(1.6 x 87 cm) followed by reverse-phase chromatography through a 
PepRPC (Hr 5/5) column using a linear gradient of acetonitrile from 
0 to 60% (30 ml) in 0.3% trifluoroacetic a id. 
3. Results 
3.1. Characterization o f  peak H antiviral peptide 
Digest ion  o f  aprot in in  by c lost r ipa in  over  a per iod  o f  
24 h at  37°C resul ted in the appearance  o f  f ragments  
wh ich  were reso lved by reverse-phase  chromatography  
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on a ProRPC Hr 16/10 colunm. A typical elution dia- 
gram is shown in Fig. 1 and consisted of five peaks. The 
fractions corresponding to each of the five peaks were 
pooled and assayed for antiviral activity. Pool I con- 
tained neither antiviral nor antibacterial ctivity but was 
cytotoxic for the cells used in the antiviral assay. Pools 
II and I I I  were antiviral for HSV-1 and PI-3 but devoid 
of antibacterial activity. Pools IV and V contained an- 
tiviral and antibacterial activities. Pool II was re-chro- 
matographed on ProRPC (Hr 5/10). The elution diagram 
from this step consisted of one major peak (Fig. 2) in 
which the antiviral activity toward HSV-1 was detected. 
This oligopeptide was sequenced and found to be Y-F-Y- 
N-A-K, corresponding to amino acids 21-26 of aprot- 
inin [7]. The oligopeptide was then artificially synthe- 
sized and purified, and the sequence and antiviral 
activity against HSV-1 were confirmed. All further 
characterizing assays were performed with the synthetic 
oligopeptide. 
3.2. Specificity of the antiviral activity of the oligopeptide, 
Y-F- Y-N-A-K 
The oligopeptide inhibited replication of HSV-1 in RD 
cells in a dose-dependent manner (Fig. 3). The 50% effec- 
tive dose (EDs0) was 38 pM. A concentraUon of 600 
/~M Y-F-Y-N-A-K reduced PI-3 replication by 25%. No 
inhibitory effects were observed against EHV-1 or 
PRCV. In order to investigate whether cell type is impor- 
tant for the inhibitory effect of the oligopeptide, the an- 
tiviral assays for HIV-1 and EHV-1 were also performed 
on VERO cells. At a concentration of 600 #M the oli- 
gopeptide did not inhibit the replication of HSV-1 if 
VERO cells were infected with the same amount of virus 
used for RD cells. Because VERO cells are 100-times 
more sensitive to HSV-1 the compound was also tested 
for inhibitory activity using 100-times less virus. Under 
this condition the oligopeptide inhibited HSV-1 replica- 
tion by 70%. No inhibition of EHV-1 replication in 
VERO cells was observed. Aprotinin assayed up to a 
concentration of 1.5 mM had no effect on the four vi- 
ruses tested. Both compounds, aprotinin and the oli- 
gopeptide, were not cytotoxic for the cells used in the 
assays. 
Preincubation of the cells with oligopeptide for 24 h 
before inoculation of the virus resulted in no antiviral 
effect. Preincubation of the virus with peptide for 1 h at 
37°C before inoculation of the cells with the mixture was 
also ineffective. Immediate addition of the virus-peptide 
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Fig. 2. Reverse-phase chromatography on ProRPC (Hr 5/10) of pool 
II from ProRPC (Hr 16/10). 
mixture to the cells without preincubation was likewise 
ineffective. 
3.3. Antibacterial activity 
The antibacterial ctivity of the hexapeptide was de- 
termined at the same protein concentration used for the 
antiviral assays. No antibacterial activity was detected 
against he following Gram-positive and -negative bacte- 
ria: E. coli, K. pneumoniae, B. subtilis, Bord. bronchisep- 
tica, S. marcescens, Staph. lentus, Staph. epidermitis, 
Staph. aureus. 
3.4. Trypsin inhibiting activity 
Antitryptic activity of the oligopeptide was assayed at 
a concentration of 1 mM. No inhibition of trypsin oc- 
curred although intact aprotinin completely inhibits 
trypsin at the same equimolar concentration. 
4. Discussion 
Digestion of aprotinin with clostripain yielded five ol- 
igopeptide fragments, four of which had antiviral activ- 
ity against HSV-1, although the native molecule xhibits 
no antiviral activity. Clostripain was previously used for 
the fragmentation f human cathepsin G, a basic enzyme 
which has antibacterial ctivity not related to its catalytic 
properties [17]. Here, only fragment II has been com- 
pletely analysed since difficulties in sequencing and pep- 
tide synthesis occurred with pools III, IV and V which 
would have unduely delayed this report. Fragment II 
(Fig. 1) consisted of the hexapeptide Y-F-Y-N-A-K, 
which corresponds to amino acids 21-26 of the aprotinin 
sequence. 
The oligopeptide did not inhibit the replication of 
EHV-1 in EHL and VERO cells and of PRCV but inhib- 
ited replication of HSV-1 in RD and VERO cells and 
PI-3 on MDBK cells. This differentiated effect indicates 
that this compound may interact with specific and, for 
some viruses, essential viral replication mechanisms. 
HSV-1 replication is inhibited by the peptide in both RD 
and VERO cells if the same multiplicity of infection, 
specific for the cell, was used. In addition EHV-1 replica- 
tion was not inhibited either on EHL or on VERO cells 
at different multiplicities of infection. Thus we conclude 
that the effect of Y-F-Y-N-A-K is not dependent on the 
cell type infected. 
The peptide was devoid of antiproteinase activity, and, 
in intact aprotinin, it is separated from the active site 
(amino acid 13-18) by 2 amino acids (19 and 20) [7]. 
Thus no relationship between antiviral activity and pro- 
teinase inhibition is indicated. 
Intact aprotinin had no effect on any of the four vi- 
ruses tested although it was previously demonstrated to
inhibit influenza virus propagation in chicken embryos 
[10]. This observation was attributed to the ability of 
aprotinin to block proteolytic activation of the virus 
spikes. However, no control experiments were per- 
formed using inactivated aprotinin. While aprotinin also 
has antibacterial properties [8,11], these are most proba- 
bly unrelated to its antiproteinase activity [11]. 
The new antiviral activity of the aprotinin-derived oli- 
gopeptide, not detectable in the original compound, con- 
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trasts with the situation of  cystatin, an inhibitor of  cyste- 
ine proteinases and a tripeptide derived therefrom [18]. 
The short oligopeptide, which corresponds to its active 
site and inhibits proteinases, also inhibits viral multipli- 
cation of  HSV-1 as does the parent molecule. This sug- 
gests that proteinase inhibition could be the underlying 
mechanism in that system. 
The cystatin- and aprotinin-derived peptides may have 
similarities concerning their site and chronology of  ac- 
tion in the virus replication cycles. This is suggested by 
the dependence of observed antiviral activity on the 
order of  addition of  virus vs. oligopeptide in both cases. 
As a prerequisite for antiviral activity, the virus had to 
be applied to the cells 1 h before the respective peptides 
were added. Since preincubation of  viruses with oli- 
gopeptides did not affect viral infectivity, we can also 
conclude that the aprotinin- and cystatin-peptides do not 
function as defensins, i.e. by directly neutralizing viruses 
[19]. Another feature common to both the cystatin and 
aprotinin oligopeptides is their requirement for pro- 
longed incubation (> 1 h) in the virus-cell system before 
suppressing viral activity. This, plus the fact that simulta- 
neous addition of  the virus and oligopeptide to the cells 
did not suppress infectivity, indicate that the oligopep- 
tide does not compete with the virus for receptor sites on 
the cell surface. Successful inhibition of  viral activity 
occurred only when the respective oligopeptide was 
added after virus adsorption and internalization and was 
continually present in the system. How the oligopeptide 
functions to inhibit viral replication remains unknown. 
It is possible that viruses alter the cell surface thereby 
providing new binding sites, or that they stimulate up- 
take of  exogenous material by the cells. Such specula- 
tions have yet to be tested as possible interaction mecha- 
nisms. 
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